Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance

Federico Cresta, Aldo Naselli, Federica Favilli, Rosaria Casciaro

Research output: Contribution to journalArticle

Abstract

The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-ABPA-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been  inhaling 7% NaCl+0.1% hyaluronic acid (HA) as a maintenance therapy. We reviewed patient database and, analysing a 7-year follow-up, considered pulmonary exacerbation, antibiotic and steroid courses, pulmonary function (forced expiratory volume in one second; FEV1) and microbiological data. After starting 7% NaCl+0.1% HA treatment, we observed a dramatic decrease of oral antibiotic need (0.55 courses/month during the pretreatment period against 0.10 courses/month in the treatment period), associated with a good initial recovery and a stability of FEV1. In our opinion this case could suggest an extended indication for inhaled 7% NaCl+0.1% HA use in CF, not only in patients who did not tolerate hypertonic saline, but also in patients with coexistent asthma-like symptoms.

Original languageEnglish
JournalBMJ Case Reports
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Hyaluronic Acid
Cystic Fibrosis
Asthma
Lung
Anti-Bacterial Agents
Respiratory Sounds
Forced Expiratory Volume
Inhalation
Therapeutics
Steroids
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms : a new therapeutic chance. / Cresta, Federico; Naselli, Aldo; Favilli, Federica; Casciaro, Rosaria.

In: BMJ Case Reports, Vol. 2013, 2013.

Research output: Contribution to journalArticle

@article{f7cd22b374534c3d803c4dbb66156e6c,
title = "Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance",
abstract = "The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-ABPA-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been  inhaling 7{\%} NaCl+0.1{\%} hyaluronic acid (HA) as a maintenance therapy. We reviewed patient database and, analysing a 7-year follow-up, considered pulmonary exacerbation, antibiotic and steroid courses, pulmonary function (forced expiratory volume in one second; FEV1) and microbiological data. After starting 7{\%} NaCl+0.1{\%} HA treatment, we observed a dramatic decrease of oral antibiotic need (0.55 courses/month during the pretreatment period against 0.10 courses/month in the treatment period), associated with a good initial recovery and a stability of FEV1. In our opinion this case could suggest an extended indication for inhaled 7{\%} NaCl+0.1{\%} HA use in CF, not only in patients who did not tolerate hypertonic saline, but also in patients with coexistent asthma-like symptoms.",
author = "Federico Cresta and Aldo Naselli and Federica Favilli and Rosaria Casciaro",
year = "2013",
doi = "10.1136/bcr-2013-009042",
language = "English",
volume = "2013",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BRITISH INST RADIOLOGY",

}

TY - JOUR

T1 - Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms

T2 - a new therapeutic chance

AU - Cresta, Federico

AU - Naselli, Aldo

AU - Favilli, Federica

AU - Casciaro, Rosaria

PY - 2013

Y1 - 2013

N2 - The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-ABPA-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been  inhaling 7% NaCl+0.1% hyaluronic acid (HA) as a maintenance therapy. We reviewed patient database and, analysing a 7-year follow-up, considered pulmonary exacerbation, antibiotic and steroid courses, pulmonary function (forced expiratory volume in one second; FEV1) and microbiological data. After starting 7% NaCl+0.1% HA treatment, we observed a dramatic decrease of oral antibiotic need (0.55 courses/month during the pretreatment period against 0.10 courses/month in the treatment period), associated with a good initial recovery and a stability of FEV1. In our opinion this case could suggest an extended indication for inhaled 7% NaCl+0.1% HA use in CF, not only in patients who did not tolerate hypertonic saline, but also in patients with coexistent asthma-like symptoms.

AB - The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-ABPA-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been  inhaling 7% NaCl+0.1% hyaluronic acid (HA) as a maintenance therapy. We reviewed patient database and, analysing a 7-year follow-up, considered pulmonary exacerbation, antibiotic and steroid courses, pulmonary function (forced expiratory volume in one second; FEV1) and microbiological data. After starting 7% NaCl+0.1% HA treatment, we observed a dramatic decrease of oral antibiotic need (0.55 courses/month during the pretreatment period against 0.10 courses/month in the treatment period), associated with a good initial recovery and a stability of FEV1. In our opinion this case could suggest an extended indication for inhaled 7% NaCl+0.1% HA use in CF, not only in patients who did not tolerate hypertonic saline, but also in patients with coexistent asthma-like symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84924924047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924924047&partnerID=8YFLogxK

U2 - 10.1136/bcr-2013-009042

DO - 10.1136/bcr-2013-009042

M3 - Article

C2 - 23632183

AN - SCOPUS:84878632278

VL - 2013

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

ER -